CCND1 and neoplasm: In the primary tumor, 15 (35.7%), 11 (26.2%), 4 (9.5%) and 4 (9.5%) patients harbored amplifications in all 3 exons of MYC, CCND1, ERBB2 and CCNE1, respectively.